Citation tools
"IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis.." The Journal of Rheumatology
35.3
(2008):
425-428.
Web. 29 Mar. 2024.